PURPOSE: To evaluate the efficacy, safety, predictability, and patient satisfaction after refractive lens exchange with a zonal refractive intraocular lens (IOL) with an inferior reading addition in emmetropic patients. SETTING: Optical Express, London, United Kingdom. DESIGN: Retrospective case series. METHODS: Emmetropic presbyopic patients who had implantation of a Lentis Mplus LS-313 MF30 IOL were evaluated. Inclusion criteria were sphere between -0.50 diopter (D) and +1.00 D with no more than 0.75 D of refractive cylinder and an uncorrected distance visual acuity (UDVA) of 6/6 or better in each eye. The main outcome measures were monocular and binocular UDVA, uncorrected near visual acuity (UNVA), corrected distance visual acuity (CDVA), and patient satisfaction. Three months data are presented. RESULTS: Four hundred forty eyes of 220 patients were evaluated. The mean monocular UDVA changed from -0.04 logMAR ± 0.06 (SD) preoperatively to -0.04 ± 0.11 logMAR postoperatively (P = .39). The mean CDVA was -0.10 ± 0.05 logMAR preoperatively and -0.09 ± 0.06 logMAR postoperatively (P = .06). At 3 months, 99.7% of eyes were within ±1.00 D of emmetropia. The mean UNVA was 0.13 ± 0.14 logMAR monocularly and 0.10 ± 0.12 logMAR binocularly. On the patient satisfaction questionnaire, 91.9% of patients said the refractive procedure improved their lives and 93.5% were willing to recommend it to friends and family. Three patients requested IOL exchange because of severe night-vision phenomena or unsatisfactory quality of vision. CONCLUSION: Refractive lens exchange with this zonal refractive IOL was safe in emmetropic presbyopic patients. FINANCIAL DISCLOSURE: Dr. Schallhorn is a consultant to Abbott Medical Optics. No other author has a financial or proprietary interest in any material or method mentioned.
PURPOSE: To evaluate the efficacy, safety, predictability, and patient satisfaction after refractive lens exchange with a zonal refractive intraocular lens (IOL) with an inferior reading addition in emmetropic patients. SETTING: Optical Express, London, United Kingdom. DESIGN: Retrospective case series. METHODS: Emmetropic presbyopic patients who had implantation of a Lentis Mplus LS-313 MF30 IOL were evaluated. Inclusion criteria were sphere between -0.50 diopter (D) and +1.00 D with no more than 0.75 D of refractive cylinder and an uncorrected distance visual acuity (UDVA) of 6/6 or better in each eye. The main outcome measures were monocular and binocular UDVA, uncorrected near visual acuity (UNVA), corrected distance visual acuity (CDVA), and patient satisfaction. Three months data are presented. RESULTS: Four hundred forty eyes of 220 patients were evaluated. The mean monocular UDVA changed from -0.04 logMAR ± 0.06 (SD) preoperatively to -0.04 ± 0.11 logMAR postoperatively (P = .39). The mean CDVA was -0.10 ± 0.05 logMAR preoperatively and -0.09 ± 0.06 logMAR postoperatively (P = .06). At 3 months, 99.7% of eyes were within ±1.00 D of emmetropia. The mean UNVA was 0.13 ± 0.14 logMAR monocularly and 0.10 ± 0.12 logMAR binocularly. On the patient satisfaction questionnaire, 91.9% of patients said the refractive procedure improved their lives and 93.5% were willing to recommend it to friends and family. Three patients requested IOL exchange because of severe night-vision phenomena or unsatisfactory quality of vision. CONCLUSION: Refractive lens exchange with this zonal refractive IOL was safe in emmetropic presbyopic patients. FINANCIAL DISCLOSURE: Dr. Schallhorn is a consultant to Abbott Medical Optics. No other author has a financial or proprietary interest in any material or method mentioned.
Authors: Alberto Domínguez-Vicent; Jose Juan Esteve-Taboada; Antonio J Del Águila-Carrasco; Teresa Ferrer-Blasco; Robert Montés-Micó Journal: Graefes Arch Clin Exp Ophthalmol Date: 2015-12-16 Impact factor: 3.117
Authors: Karol Kakarenko; Izabela Ducin; Krzysztof Grabowiecki; Zbigniew Jaroszewicz; Andrzej Kolodziejczyk; Alejandro Mira-Agudelo; Krzysztof Petelczyc; Aleksandra Składowska; Maciej Sypek Journal: Biomed Opt Express Date: 2015-04-16 Impact factor: 3.732
Authors: Peter Žiak; Juraj Halička; Peter Mojžiš; Karolína Kapitánová; Javorka Michal; David P Piñero Journal: Int Ophthalmol Date: 2019-06-05 Impact factor: 2.031
Authors: Laura J Wood; Jasleen K Jolly; Markus Groppe; Larry Benjamin; James F Kirwan; Nishal Patel; Mostafa A Elgohary; Robert E MacLaren Journal: Clin Ophthalmol Date: 2020-07-16
Authors: James A Katz; Paul M Karpecki; Alexandra Dorca; Sima Chiva-Razavi; Heather Floyd; Elizabeth Barnes; Mark Wuttke; Eric Donnenfeld Journal: Clin Ophthalmol Date: 2021-05-24